Vaccine Company Expands Partnership With The Government of Canada

In an unprecedented move that underscores the importance of innovation in the fight against infectious diseases, VBI Vaccines Inc. has expanded its strategic partnership with the Government of Canada. This collaboration, supported by a generous funding injection from the Canadian Strategic Innovation Fund (SIF), promises to accelerate the development of groundbreaking vaccine technologies, particularly VBI's novel mRNA-launched eVLP MLE Vaccine Platform. With up to CAD$56 million pledged to propel VBI's coronavirus program through Phase 2 clinical development, this partnership is not just a win for Canadian science but a beacon of hope for global health initiatives. $VBI Vaccines(VBIV.US)$